Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]IBI351 in Healthy Male Chinese Subjects
NCT05626179Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fulzerasib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by Innovent Biologics. Primary endpoints: Cumulative recovery of total radioactivity in excreta (urine and feces) at 30 days, Percentage of metabolite in total exposure AUC in plasma at 30 days and 10 more. Started Feb 2023; status: completed.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05626179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626179.